% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Siafis:279165,
      author       = {Siafis, Spyridon and Nomura, Nobuyuki and Schneider-Thoma,
                      Johannes and Bighelli, Irene and Bannach-Brown, Alexandra
                      and Ramage, Fiona J and Tinsdeall, Francesca and Mantas,
                      Ioannis and Jauhar, Sameer and Natesan, Sridhar and Vernon,
                      Anthony C and de Bartolomeis, Andrea and Hölter, Sabine M
                      and Drude, Natascha I and Tölch, Ulf and Hansen, Wulf-Peter
                      and Chiocchia, Virginia and Howes, Oliver D and Priller,
                      Josef and Macleod, Malcolm R and Salanti, Georgia and
                      Leucht, Stefan},
      title        = {{M}uscarinic receptor agonists and positive allosteric
                      modulators in animal models of psychosis: protocol for a
                      systematic review and meta-analysis [version 2; peer review:
                      1 approved, 2 approved with reservations]},
      journal      = {F1000Research},
      volume       = {13},
      issn         = {2046-1402},
      address      = {London},
      publisher    = {F1000 Research Ltd},
      reportid     = {DZNE-2025-00693},
      pages        = {1017},
      year         = {2025},
      abstract     = {Muscarinic receptor agonism and positive allosteric
                      modulation is a promising mechanism of action for treating
                      psychosis, not present in most D2R-blocking antipsychotics.
                      Xanomeline, an M1/M4-preferring agonist, has shown efficacy
                      in late-stage clinical trials, with more compounds being
                      investigated. Therefore, we aim to synthesize evidence on
                      the preclinical efficacy of muscarinic receptor agonists and
                      positive allosteric modulators in animal models of psychosis
                      to provide unique insights and evidence-based information to
                      guide drug development.We plan a systematic review and
                      meta-analysis of in vivo animal studies comparing muscarinic
                      receptor agonists or positive allosteric modulators with
                      control conditions and existing D2R-blocking antipsychotics
                      in animals subjected to any method that induces behavioural
                      changes of relevance for psychosis. We will identify
                      eligible studies by searching multiple electronic databases.
                      At least two independent reviewers will conduct the study
                      selection and data extraction using prespecified forms and
                      assess the risk of bias with the SYRCLE's tool. Our primary
                      outcomes include locomotor activity and prepulse inhibition
                      measured with standardized mean differences. We will examine
                      other behavioural readouts of relevance for psychosis as
                      secondary outcomes, such as social interaction and cognitive
                      function. We will synthesize the data using multi-level
                      meta-analysis with a predefined random-effects structure,
                      considering the non-independence of the data. In
                      meta-regressions we will explore potential sources of
                      heterogeneity from a predefined list of characteristics of
                      the animal population, model, and intervention. We will
                      assess the confidence in the evidence considering a
                      self-developed instrument thatconsiders the internal and
                      external validity of the evidence.PROSPERO-ID:
                      CRD42024520914.},
      keywords     = {Animals / Systematic Reviews as Topic / Psychotic
                      Disorders: drug therapy / Disease Models, Animal /
                      Meta-Analysis as Topic / Allosteric Regulation: drug effects
                      / Muscarinic Agonists: therapeutic use / Muscarinic
                      Agonists: pharmacology / Antipsychotic Agents: therapeutic
                      use / Antipsychotic Agents: pharmacology / antipsychotic;
                      schizophrenia; psychosis; muscarinic receptor;
                      acetylcholine; meta-analysis (Other) / Muscarinic Agonists
                      (NLM Chemicals) / Antipsychotic Agents (NLM Chemicals)},
      cin          = {AG Priller},
      ddc          = {610},
      cid          = {I:(DE-2719)5000007},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39844929},
      pmc          = {pmc:PMC11751611},
      doi          = {10.12688/f1000research.155356.2},
      url          = {https://pub.dzne.de/record/279165},
}